登录新浪财经APP 搜索【信披】查看更多考评等级 （来源：创业板观察） 今日聚焦 【仅隔三日大基金再度减持赛微电子对后者持股比例降至5%以下】 赛微电子(300456.SZ)公告称，公司持股5%以上股东国家集成电路产业投资基金股份有限公司因基金退 出需要，于2025年11月25日至2025年11月27日通过集中竞价方式合计减持642.78万股，持股比例由 5.88%下降至4.999986%，权益变动触及1%整数倍。此次减持不会导致公司控制权变更，不会对公司持 续经营产生重大影响。小财注：截至11月24日，大基金持有赛微电子5.88%股份，为公司的第二大股 东。赛微电子11月24日公告，大基金于2025年9月23日至11月24日通过集中竞价方式合计减持783.6718 万股，占公司总股本的1.07%。持股比例由6.95%降至5.88%，减持比例触及1%整数倍。 【辰安科技：拟向合肥国投发行股票可能导致公司控制权发生变更股票明起停牌】 辰安科技(300523.SZ)公告称，公司正筹划向特定对象合肥国有资本创业投资有限公司发行A股股票事 宜，可能导致公司控制权发生变更。该事项需获得反垄断部门批准、国有资产监督管理部 ...

证券代码：603566 证券简称：普莱柯 公告编号：2025-039 普莱柯生物工程股份有限公司关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准普莱柯生物工程股份有限公 司（以下简称"公司"）及全资子公司洛阳惠中生物技术有限公司（以下简称"惠中生物"）、洛阳惠中动 物保健有限公司（以下简称"惠中动保"）等单位联合申报的"猫泛白细胞减少症、杯状病毒病、鼻气管 炎三联灭活疫苗（708株+60株+64株）"为新兽药，并于2025年9月29日公示了核发《新兽药注册证书》 （中华人民共和国农业农村部公告第953号）事项。详情如下： 一、新兽药的基本信息 新兽药名称：猫泛白细胞减少症、杯状病毒病、鼻气管炎三联灭活疫苗（708株+60株+64株） 注册分类：三类 主要成分与含量：每头份疫苗中含灭活的猫泛白细胞减少症病毒708株105.7FAID50，含灭活的猫杯状 病毒60株109.0TCID50，含灭活的猫疱疹病毒1型64株107.2TCID5 ...

Core Points - The company, Pulaike, announced the approval of a new veterinary drug by the Ministry of Agriculture and Rural Affairs, which includes a trivalent inactivated vaccine for feline panleukopenia, calicivirus disease, and rhinotracheitis [1] Group 1 - The new veterinary drug is a combination vaccine consisting of strains 708, 60, and 64 [1] - The approval was granted following the review process outlined in the Veterinary Drug Management Regulations and the Veterinary Drug Registration Measures [1] - The new veterinary drug registration certificate was officially issued on September 29, 2025, as per the announcement [1]

Core Viewpoint - The company, Prike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug aimed at preventing three feline diseases, marking a significant development in its product offerings [1] Group 1: Product Approval - The new veterinary drug is a trivalent inactivated vaccine for feline panleukopenia, feline calicivirus, and feline infectious respiratory disease [1] - The vaccine was jointly submitted by the company and its wholly-owned subsidiaries, Luoyang Huizhong Biotechnology Co., Ltd. and Luoyang Huizhong Animal Health Co., Ltd. [1] - The new veterinary drug registration certificate was officially issued on September 29, 2025, as per the announcement from the Ministry of Agriculture and Rural Affairs [1] Group 2: Vaccine Efficacy - The vaccine is designed to prevent feline panleukopenia, feline calicivirus disease, and feline infectious respiratory disease [1] - The immune response is expected to develop within 7 days after the second vaccination, with an immunity duration of 12 months [1]

Core Viewpoint - The company, Prike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug aimed at preventing three feline diseases, marking a significant advancement in its product offerings [1] Group 1: Product Approval - The new veterinary drug is a trivalent inactivated vaccine for feline panleukopenia, feline calicivirus, and feline infectious respiratory disease [1] - The vaccine was jointly submitted by the company and its wholly-owned subsidiaries, Luoyang Huizhong Biotechnology Co., Ltd. and Luoyang Huizhong Animal Health Co., Ltd. [1] - The new veterinary drug registration certificate was officially issued on September 29, 2025, as per the announcement by the Ministry of Agriculture and Rural Affairs [1] Group 2: Vaccine Efficacy - The vaccine is designed to prevent feline panleukopenia, feline calicivirus disease, and feline infectious respiratory disease [1] - The immune response is expected to develop within 7 days after the second vaccination, with an immunity duration of 12 months [1]

Core Viewpoint - The company, Pulike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug, specifically a trivalent inactivated vaccine for cats, which targets feline panleukopenia, calicivirus, and rhinotracheitis [1] Group 1 - The new veterinary drug is a joint application by Pulike and its wholly-owned subsidiaries, Luoyang Huizhong Biotechnology Co., Ltd. and Luoyang Huizhong Animal Health Co., Ltd. [1] - The approval includes the issuance of the New Veterinary Drug Registration Certificate, as announced in the Ministry of Agriculture and Rural Affairs' public notice No. 953 [1] - The vaccine is expected to be publicly available by September 29, 2025 [1]